Sign in Subscribe
Diseases

Graves Disease Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved

Strategic Insights

— 1 min read

The Graves disease pipeline constitutes 8+ key companies working towards developing 10+ treatment therapies, offering new hope for patients suffering from this autoimmune disorder. The pipeline report covers a comprehensive analysis of the present clinical development scenario and growth prospects across the Graves disease market. Key companies involved in the development of Graves disease treatment therapies include Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, Hoffmann-La Roche, and others.

Key Takeaways:

  • The Graves disease pipeline includes 8+ key companies working towards developing 10+ treatment therapies.
  • Emerging therapies in different phases of clinical trials, such as Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others, are expected to have a significant impact on the Graves disease market in the coming years.
  • Breakthrough Therapy Designation has been granted to veligrotug, an intravenously administered anti-IGF-1R antibody, for the treatment of thyroid eye disease (TED) by the U.S. FDA.
  • Linsitinib, an oral small molecule candidate, has demonstrated a favorable safety profile after being tested in over 900 patients across 15 clinical trials.
  • Companies across the globe are working towards developing novel Graves disease treatment therapies with considerable success over the years.
  • Emerging therapies, such as veligrotug, CFZ533, Batoclimab, and others, are expected to play a crucial role in the Graves disease market.

Statistics:

  • 8+ key companies are working towards developing 10+ treatment therapies for Graves disease.
  • 10+ emerging therapies are in different phases of clinical trials, such as Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others.
  • The Graves disease pipeline report provides comprehensive insights into the treatment market, including the mechanism of action, clinical studies, NDA approvals, and product development activities.

Sources:

  • DelveInsight's "Graves Disease Pipeline Insight, 2025" report.
  • Amgen's announcement of UK Medicines and Healthcare products Regulatory Agency (MHRA) approval of TEPEZZA [R] (teprotumumab) for marketing in May 2025.
  • Viridian Therapeutics, Inc.'s (Nasdaq: VRDN) announcement of U.S. FDA Breakthrough Therapy Designation to veligrotug in May 2025.
  • Sling Therapeutics, Inc.'s topline efficacy and safety results from the Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED in January 2025.
  • Viridian Therapeutics, Inc.'s (NASDAQ: VRDN) announcement of positive topline results from its Phase 3 THRIVE-2 clinical trial in December 2024.

Read more